Associated Papers
An update on the monogenic causes of Parkinson's disease: Impact on patient stratification and personalised medicine.
Asmi S et al.
Ageing Research Reviews, 2026
Bridging pleiotropic mechanisms in leprosy type-1 reactions and neurodegenerative diseases.
Fava VM et al.
Scientific Reports, 2025
Cytosolic retention of HtrA2 during mitochondrial protein import stress triggers the DELE1-HRI pathway.
Bi PY et al.
Communications Biology, 2024
Combined MITOchondrial-NUCLEAR (MITO-NUCLEAR) Analysis for Mitochondrial Diseases Diagnosis: Validation and Implementation of a One-Step NGS Method.
Barretta F et al.
Genes, 2023
Parkinson's Disease, Parkinsonisms, and Mitochondria: the Role of Nuclear and Mitochondrial DNA.
Legati A et al.
Current Neurology and Neuroscience Reports, 2023
Post-translational modification and mitochondrial function in Parkinson's disease.
Luo S et al.
Frontiers in Molecular Neuroscience, 2023
Over-Mutated Mitochondrial, Lysosomal and TFEB-Regulated Genes in Parkinson's Disease.
Segur-Bailach E et al.
Journal of Clinical Medicine, 2022
Unraveling the Dichotomy of Enigmatic Serine Protease HtrA2.
Chakraborty A et al.
Frontiers in Molecular Biosciences, 2022
Dementia-related genetic variants in an Italian population of early-onset Alzheimer's disease.
Bartoletti-Stella A et al.
Frontiers in Aging Neuroscience, 2022
Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease.
Saini P et al.
Neurobiology of Aging, 2021
Understanding the Multiple Role of Mitochondria in Parkinson's Disease and Related Disorders: Lesson From Genetics and Protein-Interaction Network.
Nicoletti V et al.
Frontiers in Cell and Developmental Biology, 2021
Genetic testing of FUS, HTRA2, and TENM4 genes in Chinese patients with essential tremor.
Yan YP et al.
Cns Neuroscience & Therapeutics, 2020
Precision Health Resource of Control iPSC Lines for Versatile Multilineage Differentiation.
Hildebrandt MR et al.
Stem Cell Reports, 2019
Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study.
Tan MMX et al.
Brain : a Journal of Neurology, 2019
Mitochondrial HTRA2 Plays a Positive, Protective Role in Dictyostelium discoideum but Is Cytotoxic When Overexpressed.
Chen S et al.
Genes, 2018
The genetic architecture of mitochondrial dysfunction in Parkinson's disease.
Larsen SB et al.
Cell and Tissue Research, 2018
Molecular motion regulates the activity of the Mitochondrial Serine Protease HtrA2.
Merski M et al.
Cell Death & Disease, 2017
Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease.
Fitzgerald JC et al.
Brain : a Journal of Neurology, 2017
Mutation Analysis of HTRA2 Gene in Chinese Familial Essential Tremor and Familial Parkinson's Disease.
He YC et al.
Parkinson's Disease, 2017
Mitochondrial dysfunction in Parkinson's disease.
Bose A et al.
Journal of Neurochemistry, 2016
Exome sequencing in dementia with Lewy bodies.
Keogh MJ et al.
Translational Psychiatry, 2016
Characterization of Disease-Associated Mutations in Human Transmembrane Proteins.
Molnár J et al.
Plos One, 2016
Analysis of PRKN Variants and Clinical Features in Polish Patients with Parkinson's Disease.
Oczkowska A et al.
Current Genomics, 2015
Mutations in HTRA2 are not a common cause of familial classic ET.
Hopfner F et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2015
HTRA2 variations in Taiwanese Parkinson's disease.
Chen CM et al.
Journal of Neural Transmission (vienna, Austria : 1996), 2014
Molecular pathogenesis of Parkinson's disease: update.
Saiki S et al.
Journal of Neurology, Neurosurgery, and Psychiatry, 2012
Phosphorylation of HtrA2 by cyclin-dependent kinase-5 is important for mitochondrial function.
Fitzgerald JC et al.
Cell Death and Differentiation, 2012
Autosomal dominant parkinsonism: its etiologies and differential diagnoses.
Hattori N
Parkinsonism & Related Disorders, 2012
Novel variant Pro143Ala in HTRA2 contributes to Parkinson's disease by inducing hyperphosphorylation of HTRA2 protein in mitochondria.
Lin CH et al.
Human Genetics, 2011
What genetics tells us about the causes and mechanisms of Parkinson's disease.
Corti O et al.
Physiological Reviews, 2011
Genetic variations of Omi/HTRA2 in Chinese patients with Parkinson's disease.
Wang CY et al.
Brain Research, 2011
Altered enzymatic activity and allele frequency of OMI/HTRA2 in Alzheimer's disease.
Westerlund M et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2011
Association of Omi/HtrA2 with γ-secretase in mitochondria.
Behbahani H et al.
Neurochemistry International, 2010
Cell death pathways in Parkinson's disease: role of mitochondria.
Yao Z et al.
Antioxidants & Redox Signaling, 2009
Drosophila HtrA2 is dispensable for apoptosis but acts downstream of PINK1 independently from Parkin.
Tain LS et al.
Cell Death and Differentiation, 2009
Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Büeler H
Experimental Neurology, 2009
Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases.
Migliore L et al.
Mutation Research, 2009
Genetic susceptibility in Parkinson's disease.
Bras JM et al.
Biochimica Et Biophysica Acta, 2009
Genome-wide analysis to predict protein sequence variations that change phosphorylation sites or their corresponding kinases.
Ryu GM et al.
Nucleic Acids Research, 2009
Loss-of-function analysis suggests that Omi/HtrA2 is not an essential component of the PINK1/PARKIN pathway in vivo.
Yun J et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience, 2008
Genetic variation of Omi/HtrA2 and Parkinson's disease.
Ross OA et al.
Parkinsonism & Related Disorders, 2008
Update on the pathogenesis of Parkinson's disease.
Schulz JB
Journal of Neurology, 2008
Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls.
Simón-Sánchez J et al.
Human Molecular Genetics, 2008
Review: Familial Parkinson's disease--genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease.
Schiesling C et al.
Neuropathology and Applied Neurobiology, 2008
Biochemical aspects of the neuroprotective mechanism of PTEN-induced kinase-1 (PINK1).
Mills RD et al.
Journal of Neurochemistry, 2008